← FDA DRUG APPROVALS

FDA ANDA · ANDA077571

REPAGLINIDE

Sponsor: SUN PHARM INDS INC

APPLICATION
ANDA077571
TYPE
ANDA
ORIGINAL APPROVAL
2013-07-11
LATEST ACTION
2019-10-01
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued, None (Tentative Approval)

Products

REPAGLINIDEDiscontinued
REPAGLINIDE 2MG · TABLET · ORAL
REPAGLINIDENone (Tentative Approval)
REPAGLINIDE 0.5MG · TABLET · ORAL
REPAGLINIDEDiscontinued
REPAGLINIDE 1MG · TABLET · ORAL

Approval history

2019-10-01Labeling · Supplement 8 · standardAP
2019-10-01Labeling · Supplement 12 · standardAP
2013-07-11OriginalOtherAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →